Literature DB >> 30047830

Progressive motor impairment from a critically located lesion in highly restricted CNS-demyelinating disease.

B Mark Keegan1, Timothy J Kaufmann2, Brian G Weinshenker1, Orhun H Kantarci1, William F Schmalstieg3, M Mateo Paz Soldan4, Eoin P Flanagan1.   

Abstract

OBJECTIVE: To report progressive motor impairment from a critically located central nervous system (CNS) demyelinating lesion in patients with restricted magnetic resonance imaging (MRI)-lesion burden.
METHODS: We identified 38 patients with progressive upper motor-neuron impairment for >1 year, 2-5 MRI CNS-demyelinating lesions, with one seemingly anatomically responsible for progressive motor impairment. Patients with any alternative etiology for progressive motor impairment were excluded. A neuroradiologist blinded to clinical evaluation reviewed multiple brain and spinal-cord MRI, selecting a candidate critically located demyelinating lesion. Lesion characteristics were determined and subsequently compared with clinical course.
RESULTS: Median onset age was 47.5 years (24-64); 23 (61%) women. Median follow-up was 94 months (18-442); median Expanded Disability Status Scale Score (EDSS) at last follow-up was 4.5 (2-10). Clinical presentations were progressive: hemiparesis/monoparesis 31; quadriparesis 5; and paraparesis 2; 27 patients had progression from onset; 11 progression post-relapse. Total MRI lesions were 2 ( n = 8), 3 ( n = 12), 4 ( n = 12), and 5 ( n = 6). Critical lesions were located on corticospinal tracts, chronically atrophic in 26/38 (68%) and involved cervical spinal cord in 27, cervicomedullary/brainstem region in 6, thoracic spinal cord in 4, and subcortical white matter in 1.
CONCLUSION: Progressive motor impairment may ascribe to a critically located CNS-demyelinating lesion in patients with highly restricted MRI burden. Motor progression from a specific demyelinating lesion has implications for understanding multiple sclerosis (MS) progression.

Entities:  

Keywords:  Progressive myelopathy; demyelinating disease; magnetic resonance imaging; multiple sclerosis

Mesh:

Year:  2018        PMID: 30047830     DOI: 10.1177/1352458518781979

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  4 in total

1.  Multiple sclerosis lesions in motor tracts from brain to cervical cord: spatial distribution and correlation with disability.

Authors:  Anne Kerbrat; Charley Gros; Atef Badji; Elise Bannier; Francesca Galassi; Benoit Combès; Raphaël Chouteau; Pierre Labauge; Xavier Ayrignac; Clarisse Carra-Dalliere; Josefina Maranzano; Tobias Granberg; Russell Ouellette; Leszek Stawiarz; Jan Hillert; Jason Talbott; Yasuhiko Tachibana; Masaaki Hori; Kouhei Kamiya; Lydia Chougar; Jennifer Lefeuvre; Daniel S Reich; Govind Nair; Paola Valsasina; Maria A Rocca; Massimo Filippi; Renxin Chu; Rohit Bakshi; Virginie Callot; Jean Pelletier; Bertrand Audoin; Adil Maarouf; Nicolas Collongues; Jérôme De Seze; Gilles Edan; Julien Cohen-Adad
Journal:  Brain       Date:  2020-07-01       Impact factor: 13.501

2.  Relapse recovery: The forgotten variable in multiple sclerosis clinical trials.

Authors:  Orhun H Kantarci; Burcu Zeydan; Elizabeth J Atkinson; Brittani L Conway; Carmen Castrillo-Viguera; Moses Rodriguez
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-12-17

Review 3.  An argument for broad use of high efficacy treatments in early multiple sclerosis.

Authors:  James M Stankiewicz; Howard L Weiner
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-11-22

4.  Cerebrospinal fluid evaluation in patients with progressive motor impairment due to critical central nervous system demyelinating lesions.

Authors:  Benan Barakat; Steve Messina; Shreya Nayak; Roman Kassa; Elia Sechi; Eoin P Flanagan; Orhun Kantarci; Brian G Weinshenker; B Mark Keegan
Journal:  Mult Scler J Exp Transl Clin       Date:  2022-01-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.